Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.960
+0.060 (3.16%)
At close: Nov 7, 2025, 4:00 PM EST
2.000
+0.040 (2.04%)
After-hours: Nov 7, 2025, 7:58 PM EST
Gain Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
25
Market Cap
70.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 55.18K | -77.46K | -58.40% |
| Dec 31, 2022 | 132.64K | -1.29K | -0.96% |
| Dec 31, 2021 | 133.93K | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
GANX News
- 22 hours ago - Gain Therapeutics: Valuation Remains Low In Light Of Recently Reported Functional Improvement In PD Patients - Seeking Alpha
- 8 days ago - Gain Therapeutics to Present at Neuroscience 2025 - GlobeNewsWire
- 22 days ago - Gain Therapeutics to Attend the 2025 Maxim Growth Summit - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease - GlobeNewsWire
- 4 weeks ago - Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson's Patients at International Congress of Parkinson's Disease and Movement Disorders® - GlobeNewsWire
- 6 weeks ago - Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 - GlobeNewsWire
- 7 weeks ago - Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson's Disease - GlobeNewsWire
- 2 months ago - Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation - GlobeNewsWire